Fingerprint
Dive into the research topics of 'Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome
Aaron T. Gerds, Bart L. Scott, Peter Greenberg, Tara L. Lin, Daniel A. Pollyea, Amit Verma, Monique Dail, Yuning Feng, Cherie Green, Connie Ma, Bruno C. Medeiros, Mark Yan, Kasra Yousefi, William Donnellan
Research output: Contribution to journal › Article › peer-review
12
Scopus
citations